Our project portfolio also includes three drug development projects. All further development efforts are however put on hold for these, except for business partnering efforts. This to enable full focus on succeeding with the two novel cosmetic dermatology assets, Follicopeptide and NPP-4.
FOL026 belongs to the same peptide family as Follicopeptide and is Coegin Pharma's drug candidate for the treatment of myocardial infarction ("heart attack"). By repairing damaged and ischemic tissue, FOL026 has great potential to become a first-in-class medication. Preclinical studies have shown that FOL026 can repair damaged and ischemic tissue, in particular blood vessels, and protect the tissue against stress (e.g. caused by high blood pressure, high blood lipids, and/or diabetes). FOL026 is currently in the preclinical phase of development.
AVX420 is Coegin Pharma’s drug candidate for the treatment of leukemia ("blood cancer"). The project is based on a unique treatment concept specifically targeting the inhibition of cPLA₂α, an enzyme known to play a key role in tumour development. AVX420 has shown promising results in several preclinical models for leukemia and the unique aspect of AVX420 is that the molecule attacks cancer in multiple ways. AVX420 is currently in the preclinical phase of development.
AVX001 is Coegin Pharma’s drug candidate for the topical treatment of both actinic ("solar") keratosis and basal cell carcinoma, both very common types of skin cancer. This drug candidate is also based on the company’s technology platform that inhibits the enzyme cPLA₂α, an enzyme known to play a key role in tumour development. AVX001 is currently in the clinical phase 2 stage of development.
We welcome conversations with potential partners interested in bringing this innovation to their markets. Our flexible partnership models range from ingredient supply to ready-to-market formats. We’re actively exploring licensing, distribution and go-to-market strategies in key regions.